Skip to main content
Article thumbnail
Location of Repository

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

By Y H Park, M J Park, S H Ji, S Y Yi, D H Lim, D H Nam, J-I Lee, W Park, D H Choi, S J Huh, J S Ahn, W K Kang, K Park and Y-H Im


In patients with human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer, treatment with trastuzumab has been shown to markedly improve the outcome. We investigated the role of trastuzumab on brain metastasis (BM) in HER2-positive breast cancer patients. From 1999 to 2006, 251 patients were treated with palliative chemotherapy for HER2-positive metastatic breast cancer at Samsung Medical Center. The medical records of these patients were analysed to study the effects of trastuzumab on BM prevalence and outcomes. Patients were grouped according to trastuzumab therapy: pre-T (no trastuzumab therapy) vs post-T (trastuzumab therapy). The development of BM between the two treatment groups was significantly different (37.8% for post-T vs 25.0% for pre-T, P=0.028). Patients who had received trastuzumab had longer times to BM compared with patients who were not treated with trastuzumab (median 15 months for post-T group vs 10 months for pre-T group, P=0.035). Time to death (TTD) from BM was significantly longer in the post-T group than in the pre-T group (median 14.9 vs 4.0 months, P=0.0005). Extracranial disease control at the time of BM, 12 months or more of progression-free survival of extracranial disease and treatment with lapatinib were independent prognostic factors for TTD from BM

Topics: Clinical Studies
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2004). CNS metastases in breast cancer.
    2. (2004). Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.
    3. (2004). Risk of brain metastases in HER2/neu-positive breast cancer. J Clin Oncol 22: 47s
    4. (2006). Trends in breast cancer by race and ethnicity: update

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.